Why Collegium Pharmaceutical Shares Are Gaining Today
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced FY24 financial
Verizon Communications Analyst Turns Bullish, Expects Superior 2024 Performance Over T-Mobile, AT&T
Shares of Verizon Communications Inc.
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday.
Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a preliminary non-binding acquisition offer.
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?
Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary
Insiders Buying Empire Petroleum And 2 Other Stocks
Although U.S. stocks closed mostly lower on the first trading day of 2024, there were a few notable insider trades.
Jim Cramer Says Move On From This Energy Stock: ‘It’s Moved Too Much’
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended moving on from Tidewater Inc. (NYSE: TDW). "It’s moved too much," he added.
What’s Going On With AST SpaceMobile Stock Wednesday?
AST SpaceMobile Inc (NASDAQ: ASTS) shares are trading higher Wednesday. The company provided an interim update on fundraising progress.
3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street’s Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Top 4 Risk Off Stocks That May Collapse This Month
As of Jan. 3, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today?
Dyne Therapeutics Inc (NASDAQ: DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD)